High-Dose Methotrexate Pharmacokinetics and Outcome of Children and Young Adults with Osteosarcoma

Cancer

Volumn 100, Issue 8, 2004, Pages 1724-1733

  Crews, Kristine R ^a,b,c   Liu, Tieben ^c   Rodriguez Galindo, Carlos ^b,c   Tan, Ming ^b   Meyer, William H ^b,c   Panetta, J Carl ^a   Link, Michael P ^d   Daw, Najat C ^b,c  

^a St Jude Children's Research Hospital   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Cisplatin; Ifosfamide; Pediatrics; Pharmacokinetics; Treatment

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OUTCOMES RESEARCH; PEDIATRICS; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY DISEASES; MALE; METHOTREXATE; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 1842582000     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20152     Document Type: Article

References (42)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-1606.
2. Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol. 1989;16:312-322.
3. Link MP. The Multi-Institutional Osteosarcoma Study: an update. Cancer Treat Res. 1993;62:261-267.
4. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
5. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
6. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001;19:171-182.
7. Isacoff WH, Townsend CM, Eiber FR, Forster T, Morton DL, Block JB. High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Med Pediatr Oncol. 1976;2:319-325.
8. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630-634.
9. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol. 1979;3:161-166.
10. Crom WR, Pratt CB, Green AA, et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol. 1984;2:655-661.
11. Jaffe N, Keifer R III, Robertson R, Cangir A, Wang A. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. Cancer. 1987;59:1577-1581.
12. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994;12:1443-1451.
13. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual tumor. Am J Pediatr Hematol Oncol. 1994;16:286-295.
14. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol. 2000; 22:112-118.
15. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother. 1988;42:257-262.
16. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672.
17. Gibaldi M, Perrier D. Multicompartment models. In: Gibaldi M, Perrier D, editors. Pharmacokinetics., 2nd edition. New York: Marcel Dekker, Inc., 1982:45-111.
18. Schwartz GJ, Haycock GB, Edelmann CM Jr., Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259-263.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
21. Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15:265-292.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc. 1958;53:457-481.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35:1-39.
24. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:187-220.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
26. Wang YM, Sutow WW, Romsdahl MM, Perez C. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep. 1979;63:405-410.
27. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
28. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911-7.
29. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco I, Baker A et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop. 1991;270:8-14.
30. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-77.
31. [No authors listed.] Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group. Cancer. 1988;61:1304-1311.
32. Winkler K, Bieling P, Bielack S, et al. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop. 1991;270:79-86.
33. Burgers JM, van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer. 1988;61: 1024-1031.
34. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
35. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984;2:617-624.
36. Kozakewich H, Perez-Atayde AR, Goorin AM, Wilkinson RH, Gebhardt MC, Vawter GF. Osteosarcoma in young children. Cancer. 1991;67:638-642.
37. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer. 1992; 69:698-708.
38. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
39. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma-preliminary results of the Rizzoli's 4th study. Acta Oncol. 1998;37:41-48.
40. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
41. Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res. 1978;38:345-353.
42. Browman GP, Goodyear MD, Levine MN, Russell R, Archibald SD, Young JE. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol. 1990;8:203-208.